Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study

We investigated changes in clinical characteristics of SGLT2i and GLP-1RA real-world initiators in Denmark before/after landmark cardiovascular outcome trials. We compared first-time SGLT2i (25,070) and GLP-1RA (14,671) initiators to initiators of DPP-4i (n = 34,079), a class without proven cardiova...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-03, Vol.15 (3), p.e0229621-e0229621
Hauptverfasser:	Knudsen, Jakob S, Baggesen, Lisbeth M, Lajer, Maria, Nurkanovic, Larisa, Ustyugova, Anastasia, Sørensen, Henrik T, Thomsen, Reimar W
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Angina pectoris Arteriosclerosis Atherosclerosis Biology and Life Sciences Canagliflozin Cardiovascular diseases Clinical trials Comorbidity Comparative analysis Dapagliflozin Diabetes Diseases Dulaglutide Empagliflozin Epidemiology Exenatide Health care information services Heart failure Hospitals Hypoglycemic agents Initiators Liraglutide Lixisenatide Marital status Medicine and Health Sciences Mortality Obesity Patients People and places Population Population studies Population-based studies Prescription drugs Retirement benefits Semaglutide Social Sciences Therapy Time Trends Type 2 diabetes Weight control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!